DRMA Dermata Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology close Oct 2, 2026DRMA Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
DRMA Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
| Ex-date | Split | Type |
|---|---|---|
| Aug. 1, 2025 | 1-for-10 | Reverse |
| May 16, 2024 | 1-for-15 | Reverse |
| March 14, 2023 | 1-for-16 | Reverse |
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Not enough fundamentals data to compute this ratio group yet.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Not enough fundamentals data to compute this ratio group yet.
Financial Health Debt, liquidity, solvency — balance sheet strength
Not enough fundamentals data to compute this ratio group yet.
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 11, 2026 | $-0.74 | $-0.56 | -31.9% |
| March 31, 2026 | May 13, 2026 | $-0.48 | $-0.54 | 11.2% |
| Dec. 31, 2025 | $-1.52 | $-1.57 | 3.2% | |
| Sept. 30, 2025 | $-1.65 | $-1.62 | -1.7% | |
| June 30, 2025 | $-1.66 | $-2.96 | 43.9% | |
| March 31, 2025 | $-4.50 | $-4.59 | 2.0% | |
| Dec. 31, 2024 | $-20.60 | $-15.30 | -34.6% |
Institutional owners (13F) 13 filers · $158K total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 7 (+3 vs prior Q) | 1 (-3 vs prior Q) | 1 (0 vs prior Q) | 2 (+1 vs prior Q) | +16K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | $26,061 | 20,203 | 16.49% | Shares |
| Welch & Forbes LLC | $25,800 | 20,000 | 16.32% | Shares |
| STATE STREET CORP | $24,184 | 18,747 | 15.30% | Shares |
| UBS Group AG | $21,667 | 16,796 | 13.71% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $20,626 | 15,989 | 13.05% | Shares |
| XTX Topco Ltd | $19,075 | 14,787 | 12.07% | Shares |
| Advisory Alpha, LLC | $12,900 | 10,000 | 8.16% | Shares |
| Tower Research Capital LLC (TRC) | $4,979 | 3,860 | 3.15% | Shares |
| MCF Advisors LLC | $2,235 | 1,732 | 1.41% | Shares |
| BARCLAYS PLC | $348 | 270 | 0.22% | Shares |
| SBI Securities Co., Ltd. | $130 | 101 | 0.08% | Shares |
| HIGHLINE WEALTH PARTNERS LLC | $34 | 26 | 0.02% | Shares |
| MORGAN STANLEY | $3 | 2 | 0.00% | Shares |
Activists & 5%+ owners 4 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Kyri K. Van Hoose | June 1, 2026 | 9.00% | Initial filing | Passive investment | SEC |
| PROEHL GERALD T ×7 filings | Feb. 23, 2026 | 17.30% | Amendment | · | SEC |
| David Hale, Hale BioPharma Ventures LLC ×2 filings | March 31, 2023 | · | Initial filing | · | SEC |
| Gerald T. Proehl, Proehl Investment Ventures LLC ×4 filings | March 30, 2023 | · | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 13 insiders · 5 officers · 8 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| PROEHL GERALD T | President, CEO and Chairman | Jan. 2, 2026 A | 122,563 | 0 | 0 | $0 |
| Kyri K. Van Hoose | SVP, CFO | Jan. 2, 2026 A | 130,423 | 0 | 0 | $0 |
| Thomas Insley | Chief Financial Officer | Aug. 17, 2021 C | 14,337 | 0 | 0 | $0 |
| Munera Maria E Bedoya-Toro | SVP, Regulatory Affairs | Feb. 17, 2026 P | 1,012 | 1 | 0 | $1,270 |
| Christopher J. Nardo | Senior VP, CDO | Jan. 2, 2026 A | 2,439 | 0 | 0 | $0 |
| Brittany Bradrick | Director | Jan. 2, 2026 A | 23,443 | 0 | 0 | $0 |
| Kathleen D. Scott | Director | Jan. 2, 2026 A | 27,145 | 0 | 0 | $0 |
| Andrew Seth Sandler | Director | Jan. 2, 2026 A | 24,184 | 0 | 0 | $0 |
| Steven J Mento | Director | Jan. 2, 2026 A | · | 0 | 0 | $0 |
| Mary Fisher | Director | Jan. 2, 2026 A | 196,946 | 0 | 0 | $0 |
| Wendell Wierenga | Director | Jan. 2, 2026 A | 62,398 | 0 | 0 | $0 |
| HALE DAVID F | Director | Jan. 2, 2026 A | 80,957 | 0 | 0 | $0 |
| Proehl Investment Ventures LLC | 10% owner | Aug. 17, 2021 C | 2,905,544 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
DRMA Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
1 analysts · 2026-09-28Mean target $4.00 +262.0%
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.